AAV2 GDNF

Drug Profile

AAV2 GDNF

Alternative Names: AAV2-GDNF; AMT-140

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator uniQure
  • Developer Lund University; National Institute of Neurological Disorders and Stroke; uniQure; University of California at San Francisco
  • Class Antiparkinsonians; Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Sweden (Intracerebral, Infusion)
  • 30 Sep 2014 The University of California San Francisco and the National Institute of Neurological Disorders and Stroke complete treatment of patients in the first dose cohort in the phase I trial in Parkinson's disease
  • 01 Aug 2013 AAV2 GDNF - uniQuire is available for licensing as of 01 Aug 2013. http://www.uniqure.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top